Mammography reading is faced with an increasing volume of data from multiple sources, staff shortages, and more intricate reading due to the rise of tomosynthesis in national screening programs. Radiologists are challenged with an increased workload and are often under pressure to produce results faster. As the digital transformation of healthcare continues, advanced, multimodal visualization solutions for breast health are needed to transform clinical operations.
MAMMOVISTA B.smart: Full spectrum. Exceptional performance.
MAMMOVISTA B.smart covers the full spectrum of multimodal diagnostics from mammography to MRI and ultrasound. An agile, vendor-neutral solution, it delivers exceptional performance for radiologists faced with more time-consuming tomosynthesis reading.
Explore the features of MAMMOVISTA B.smart
Features & Benefits
Designed for speed
Operational performance and reading speed has the potential to increase significantly with up to 75%3 faster image loading, while next-gen AI1 help increase diagnostic accuracy by 10%4. The full spectrum of multimodality data, tools, and settings are immediately available without leaving the application, which saves both time and effort while strengthening diagnostic confidence.
Delightful to use
Intuitiveness and ease of use are essential success criteria for any domain-specific software interface used for intricate clinical or therapeutic decision making. MAMMOVISTA B.smart features a game-changing new interface based on the SHUI2 design framework that is absolutely delightful to use.
Connected for real outcomes
Clear clinical values stems from optimizing the management of growing workloads: Combining faster reading performance with AI-powered tools1, MAMMOVISTA B.smart improves your economic performance with up to 15% optimized TCO costs3 and a 35%6 reduction in workload.
Best Fit: MAMMOMAT Revelation and MAMMOVISTA B.smart
- Experience the highest depth resolution7 with the unique 50° wide-angle tomosynthesis of MAMMOMAT Revelation combined with syngo.Breast Cares smart and fast tomo reading
- Stay on top of clinical developments with integrated TiCEM8 and Insight BD2, a universal multimodality approach for comprehensive breast care reading
- Deliver instant risk stratification with Insight BD’s8 ideally-adapted layouts and Multiple ReportFlows
„Artificial intelligence could mean that one of the two radiologists reading the patient’s breast images could take on other tasks in future since the second evaluation can be done automatically.”
"Its like having an additional colleague at the press of a button."
This feature is an option and available with MAMMOVISTA B.smart. Transpara® Powered by FusionAI, ScreenPoint Medical.
SHUI stands for Siemens Healthineers User Interface.
Data on file.
FDA wide-angle DBT reader study with Transpara, approval number K193229.
K. Lang, ECR 2020 / RPS 605b - Can artificial intelligence reduce the interval cancer rate in mammography screening?
Dahlblom, A. Tingberg, S. Zackrisson, M. Dustler, Personalised breast cancer screening with selective addition of digital breast tomosynthesis through artificial intelligence, Proc. SPIE 11513, 15th International Workshop on Breast Imaging (IWBI2020), 115130C (22 May 2020); doi: 10.1117/12.2564344.
A. Lauritzen. ECR 2020 / RPS 702 - Reducing the radiologist’s workload by detecting normal mammograms with an AI system.
Using AI to triage which screening mammograms benefit from a double reading strategy. C Balta, PhD, Nijmegen, Netherlands; A Rodriguez-Ruiz; C Mieskes; N Karssemeijer, PhD; S H Heywang-Koebrunner, MD. RSNA 2020.
Maldera et al. (2016): Digital breast tomosynthesis: Dose and image quality assessment. Physica Medica, pp. 1-12.; Marshall N.W. and Bosmans H. (2012): Measurements of system sharpness for two digital breast tomosynthesis systems. Phys. Med. Biol. 57, pp. 7629-7650.; Rodríguez-Ruiz A. et al. (2016): Evaluation of the technical performance of three different commercial digital breast tomosynthesis systems in the clinical environment. Physica Medica 32, pp. 767-777.
MAMMOVISTA B.smart is under development and not commercially available. Its future availability cannot be ensured.
Syngo Carbon is not commercially available in all countries. Due to regulatory reasons its future availability cannot be guaranteed. Please contact your local Siemens Healthineers organization for further details.
The statements by Siemens Healthineers' customer described herein are based on results that were achieved in the customer's unique setting. Since there is no "typical" hospital and many variables exist (e.g. hospital size, case mix, level of IT adoption) there can be no guarantee that other customers will achieve the same results.